High Deployment: Also Trending with Balloon Expandable Valves

Conventional implantation of balloon expandable SAPIEN-3 results in a final 70:30 or 80:20 ratio of the valve in the aorta/left ventricular outflow tract.

El implante alto también es tendencia para la válvula balón expandible

This comes with permanent pacemaker implantation rates of approximately 10%. Higher deployment might translate into lower rates of conduction abnormalities and pacemaker implantation.  

The study compared a cohort of 1028 consecutive patients; 406 of these patients (39.5) received high deployment vs. conventional deployment.  

Mean implantation depth under the noncoronary cusp was significantly smaller with high deployment vs conventional technique (1.5±1.6 versus 3.2±1.9 mm; P<0.001). 

Implantation was 100% successful with both techniques. There were no cases of conversion to open heart surgery, second valve implantation within the first transcatheter aortic valve replacement, or coronary occlusion. Only one patient (0.2%) presented embolization with high deployment. 

The need for pacemaker implantation 30 days after procedure was significantly lower high deployment (5.5% vs 13.1%; p<0.001), as were rates of complete heart block (3.5% versus 11.2%; P<0.001) and new onset left bundle branch block (5.3% versus 12.2%; P<0.001).


Read also: Should Total Occlusion Influence on Revascularization Strategy?


There were no differences in mild leak (16.5% vs 15.9%; p=0.804) or moderate to severe leak (1% vs 2.7%; p=0.081) at one-year followup. 

Doppler velocity index was similar in both groups, but the high deployment technique showed slightly higher 1-year mean gradients and peak gradients.

Conclusion

High deployment of self-expandable SAPIEN-3 valves significantly reduces conduction abnormalities and pacemaker implantation rates without compromising safety. 

Original Title: Systematic Approach to High Implantation of SAPIEN-3 Valve Achieves a Lower Rate of Conduction Abnormalities Including Pacemaker Implantation.

Reference: Yasser Sammour et al. Circ Cardiovasc Interv. 2021 Jan;14(1):e009407. DOI: 10.1161/CIRCINTERVENTIONS.120.009407.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Contemporary Challenges in Left Atrial Appendage Closure: Updated Approach to Device Embolization

Even though percutaneous left atrial appendage (LAA) closure is generally safe, device embolization – with 0 to 1.5% global incidence – is still a...

Cardiac Remodeling After Percutaneous ASD Closure: Should It Be Immediate or Progressive?

Atrial septal defect (ASD) is a common congenital heart disease that generates a left-to-right shunt, leading to right-side chamber overload and a risk of...

Is it really necessary to monitor all patients after TAVR?

Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....

Is it really necessary to monitor all patients after TAVR?

Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

COILSEAL: Use of Coils in Percutaneous Coronary Intervention, Useful for Complication Management?

The use of coils as vascular closing tool has been steadily expanding beyond its traditional role in neuroradiology into coronary territory, where it remains...

Treatment of In-Stent Restenosis in Small Vessels with Paclitaxel-Coated Balloons

Coronary artery disease (CAD) in smaller epicardial vessels occurs in 30% to 67% of patients undergoing percutaneous coronary intervention and poses particular technical challenges....

Contemporary Challenges in Left Atrial Appendage Closure: Updated Approach to Device Embolization

Even though percutaneous left atrial appendage (LAA) closure is generally safe, device embolization – with 0 to 1.5% global incidence – is still a...